Newswire (Published: Tuesday, February 7, 2017, Received: Thursday, February 2, 2017, 9:21:28 PM CST)

Word Count: 349

Reports Summarize Prostate Cancer Findings from Department of Medical Oncology (Docetaxel in the treatment of castrate resistant advanced prostate cancer: a paradigm in change)

By a News Reporter-Staff News Editor at Cancer Weekly -- New research on Oncology - Prostate Cancer is the subject of a report. According to news reporting out of Bucharest, Romania, by NewsRx editors, research stated, "Until last year, the international guidelines recommended the use of docetaxel in advanced prostate cancer (PC) at the time of progression following androgen deprivation therapy (ADT). Nevertheless, two randomized phase III trials, CHAARTED and STAMPEDE, delivered level I evidence showing that upfront introduction of docetaxel, during the androgen sensitive course of disease, is able to significantly improve the patients' overall survival."

Our news journalists obtained a quote from the research from the Department of Medical Oncology, "As such, this strategy was rapidly included in the current guideline recommendations, with slightly different indications in the ESMO as compared to the NCCN version. Side effects of chemotherapy along with the possible higher benefit in high vs low-volume metastatic disease should be taken into consideration when choosing this alternative."

According to the news editors, the research concluded: "The present paper makes a review of the current data supporting the new indication of docetaxel, and provides detailed information in order to assist the clinician in deciding the best treatment for patients with advanced PC."

For more information on this research see: Docetaxel in the treatment of castrate resistant advanced prostate cancer: a paradigm in change. Journal of Buon, 2016;21(6):1379-1382 (see also Oncology - Prostate Cancer).

Our news journalists report that additional information may be obtained by contacting M. Dediu, Sanador Hospital Bucharest, Dept. of Medical Oncology, Bucharest, Romania. Additional authors for this research include F. Bratu, M. Amarandei and E. Fejer.

Keywords for this news article include: Antineoplastics, Pharmaceuticals, Europe, Romania, Oncology, Bucharest, Prostate Cancer, Docetaxel Therapy, Mitotic Inhibitors, Drugs and Therapies, Prostatic Neoplasms.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC


      Healthcare Facilities


Eastern Europe


Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Medical Specialties and Practices
            Internal Medicine
      Treatments and Therapies
            Medicinal Drugs